瘤微环境中的瘤培养细胞:免疫疗法耐药性的关键驱动因素
Ji'an Zou1, Shuxing Wang1, Yingzhe Zhang1
1Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, China.
概括
在瘤微环境 (TME) 中,瘤培养细胞 (TEC) 促进癌症生长和免疫疗法耐药性. 针对这些受瘤影响的细胞提供了一种改善抗癌疗法的新策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 针对CTLA-4,PD-1和PD-L1的免疫疗法已经推进了固体瘤治疗.
- 患者对这些疗法的耐药性仍然是一个重大的临床挑战.
- 瘤微环境 (TME) 通过细胞相互作用对免疫疗法的疗效进行了关键调节.
研究的目的:
- 审查TME中瘤培养细胞 (TEC) 的作用.
- 探索瘤形成和TEC功能的机制.
- 讨论TEC对瘤进展和免疫疗法耐药性的影响.
主要方法:
- 在TME中对TEC研究的文献综述.
- 对细胞相互作用和参与瘤形成的信号通路的分析.
- 对TEC对癌症生长和治疗耐药性的贡献的综合发现.
主要成果:
- 瘤细胞教育非瘤细胞,产生具有免疫抑制表型的TEC.
- TECs促进瘤进展和抵抗抗癌疗法.
- 瘤细胞和TEC之间的相互作用重塑TME,促进免疫逃避.
结论:
- TECs是瘤进展和免疫疗法耐药性的关键调解者.
- 了解瘤教育机制对于开发新型治疗策略至关重要.
- 针对TECs是一个有希望的方法来增强当前的癌症治疗方法.
相关概念视频
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
01:27Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
02:38Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K